Frequency and Clinical Utility of Olfactory Dysfunction in COVID-19: a Systematic Review and Meta-analysis.

摘要: Olfactory dysfunction (OD) has been gaining recognition as a symptom of COVID-19, but its clinical utility not well defined. To quantify the identifying OD in diagnosis COVID-19 and determine an estimate frequency amongst these patients. PubMed was searched up to 1 August 2020. Meta-analysis A included studies if they compared positive patients (proven by reverse transcription polymerase chain reaction) negative controls. B described symptoms were explicitly asked questionnaires or interviews smell tests performed. The pooled (17,401 patients, 60 studies) 0.56 (0.47–0.64) differs between detection via testing (0.76 [0.51–0.91]) survey/questionnaire report (0.53 [0.45–0.62]), although reaching statistical significance (p = 0.089). Patients with reported more likely test for (diagnostic odds ratio 11.5 [8.01–16.5], sensitivity 0.48 (0.40 0.56), specificity 0.93 (0.90 0.96), likelihood 6.10 (4.47–8.32) 0.58 (0.52–0.64)). There significant heterogeneity possible publication bias. Frequency greatly across studies. Nevertheless, significantly COVID-19. Patient-reported is highly specific which should be part pre-test screening suspect